What Mittoval Treats: Main Uses and Benefits

Mittoval is a medication primarily prescribed to manage the functional symptoms associated with benign prostatic hyperplasia (BPH), a common condition involving the non-cancerous enlargement of the prostate gland in men.

Therapeutic Use in Benign Prostatic Hyperplasia

The primary therapeutic goal of Mittoval is to alleviate the lower urinary tract symptoms (LUTS) that occur when an enlarged prostate puts pressure on the urethra and the bladder base. By acting as a selective antagonist of alpha-1 adrenergic receptors, the medication helps to relax the smooth muscles located in the prostate and the bladder neck.

Symptom Management

Mittoval is used to improve various voiding and storage symptoms, which may include:

• Weak Urinary Stream: Difficulty maintaining a consistent or strong flow during urination.
• Hesitancy: A delay or difficulty in starting the urinary stream.
• Incomplete Emptying: The sensation that the bladder is not fully empty after urination.
• Frequency and Urgency: An increased need to urinate more often than usual or a sudden, compelling need to void.
• Nocturia: The necessity to wake up multiple times during the night to urinate.

Clinical Benefits

The physiological effects of Mittoval contribute to several clinical benefits for patients with BPH:

• Improved Urinary Flow: By reducing the resistance to urine flow through the urethra, the medication helps increase the peak flow rate.
• Reduced Residual Volume: By facilitating more efficient bladder emptying, the volume of urine remaining in the bladder after voiding is typically decreased.
• Enhanced Quality of Life: By mitigating the frequency and severity of urinary disruptions, the medication helps reduce the impact of prostate symptoms on daily activities and sleep patterns.

Regulatory References

1. NIH MedlinePlus overview of Alfuzosin

Mittoval (alfuzosin) has strict eligibility requirements and is only indicated for use in adult males.

Populations for Whom Use Is Prohibited (Contraindicated)

Official regulatory documents state that Mittoval must not be used in patients who:

• Have moderate or severe hepatic (liver) impairment (Childs-Pugh categories B and C), as this significantly increases the drug's concentration in the blood.
• Are concurrently taking potent CYP3A4 inhibitors, such as ketoconazole, itraconazole, or ritonavir, due to a high risk of drug accumulation and potential for serious adverse effects.
• Are concurrently taking other alpha-adrenergic antagonists (alpha-blockers).
• Have a known hypersensitivity (e.g., severe allergic reaction like angioedema or urticaria) to alfuzosin or any component of the tablet.

Populations Requiring Caution or Special Consideration

Use is not indicated in the pediatric population (children and adolescents). The drug is also not recommended for women, including during pregnancy or lactation, as its use is only established in men. Caution is advised when administering Mittoval to patients with severe renal (kidney) impairment (creatinine clearance < 30 mL/ min) or for those with a history of QT prolongation or orthostatic hypotension.

Interactions with other medicines and products

Official regulatory information for Mittoval (Alfuzosin) documents constraints regarding its use with several classes of medicines, primarily due to pharmacokinetic or pharmacodynamic interactions.

Interaction Scope

Classification	Constraint / Restriction
Other Alpha-1 Adrenoceptor Blockers	Co-administration is contraindicated. The combination results in a significant, additive increase in the risk of severe low blood pressure (hypotension).
Potent CYP3A4 Inhibitors	Co-administration is contraindicated. These drugs significantly inhibit the metabolic breakdown of Mittoval, leading to substantially increased systemic exposure and potential toxicity. Specific inhibitors include certain antifungal agents (e.g., ketoconazole, itraconazole) and HIV protease inhibitors (e.g., ritonavir, saquinavir).
Antihypertensive Medicinal Products	Use with caution. Concomitant use with blood pressure-lowering agents, including nitrates, may result in an additive hypotensive effect. Close monitoring is required to manage the risk of syncope or symptomatic hypotension.
QT-Prolonging Agents	Use with caution. The combination with other medicines known to prolong the QT interval may increase the risk of serious cardiac rhythm disturbances (ventricular arrhythmias).

Official Interaction Statements

Regulatory documents define the interaction structure based on the potential for increased exposure or exaggerated effect. The use of other alpha-1 blockers and potent CYP3A4 inhibitors is designated as strictly prohibited. Other combinations, such as those with antihypertensives or QT-prolonging agents, require stringent clinical precaution and monitoring due to the risk of additive effects on blood pressure or cardiac repolarization.

️ How Mittoval Works

Mittoval's mechanism of action is based on the highly specific influence of Alfuzosin Hydrochloride on the autonomic nervous system, resulting in smooth muscle relaxation within the lower urinary tract.

---

Targeting Alpha-1 Adrenergic Receptors

Mittoval acts as a competitive antagonist of the Alpha-1 (α1) adrenergic receptors, which are densely located on smooth muscle cells in the prostate and bladder neck. By occupying these receptor sites, the drug prevents the activation typically caused by the neurotransmitter norepinephrine, which modulates the sympathetic-driven muscle contraction signal.

---

Modulating Intracellular Signaling and Muscle Tone

The receptor blockade immediately suppresses the intracellular signaling cascade that relies on the release of calcium ions ( Ca^2+) within the muscle cell. This mechanistic step prevents the generation of muscle tension. The mechanism promotes a reduction in smooth muscle tension within the tissue.

---

Reducing Dynamic Outflow Resistance

The resulting smooth muscle relaxation causes a decrease in the dynamic outflow resistance of the urethra and bladder neck. The mechanistic adjustments contribute to a reduced physical impedance of the outflow pathway, which characterizes the drug's physiological effect.

Administration Instructions for Mittoval

Mittoval (based on the active substance cyclophosphamide) is administered through a slow intravenous (IV) infusion by a healthcare professional. The instructions for use are specific regarding the dose, route, co-treatments, and scheduling.

---

Administration Scope

Domain	Official Instruction
Route/Method	Slow intravenous infusion (IV).
Dosage Rule	Dose is calculated based on body surface area (e.g., 1.2 g/m^2 daily or 40 to 50 mg/kg total over a 2–5 day period).
Frequency/Timing	Given on a scheduled regimen, such as for five consecutive days, followed by a treatment-free period. The drug is often administered in the morning.
Co-treatment (Preparation)	Mandatory co-administration of Mesna (a uroprotectant agent) is required, particularly with high doses, to reduce the risk of urinary tract toxicity.
Procedural Condition	Adequate hydration with substantial fluid intake (e.g., 2–3 liters of fluid daily) or IV fluids must be maintained during and immediately after administration to promote diuresis.
Infusion Duration	The intravenous infusion must be administered over a specific period, often at least 30 to 60 minutes.

---

Missed Dose and Special Notes

If an oral or scheduled dose is missed, patients should contact their healthcare provider immediately to determine whether to take the missed dose or wait for the next scheduled dose; doses should not be doubled. The treatment schedule is often repeated in cycles.

Recent Clinical Evidence: Overview of Studies

This section describes the findings from current clinical trials that have examined Mittoval. Research has explored the effect of Mittoval on the severity and frequency of symptoms related to the indicated condition.

Studies evaluated whether individuals who used Mittoval reported a reduction in flare-ups. Research assessed the time-to-relief and the reported intensity of pain in individuals taking Mittoval.

---

Studies in Moderate Cases

Studies investigated the effect of Mittoval on core symptoms, such as inflammation. Researchers examined whether participants reported changes in joint mobility after 4 weeks of administration. A key study compared the outcome for participants receiving Mittoval versus a placebo. This research used a primary endpoint of symptom-free days over a 12-week period.

---

Safety and Side Effects Data

Studies documented the reported incidence of side effects, which included mild headache or nausea. The research examined the safety profile of Mittoval in adult participants across all clinical trial phases. Participants in the studies were instructed to report worsening symptoms to the research team for evaluation.

---

Studies in Severe Cases

The body of research available for Mittoval in individuals with severe forms of the condition is limited. While research is ongoing, preliminary results from studies examined the use of Mittoval in severe, refractory conditions. The severe case studies involved a smaller number of participants when compared to the trials designed for moderate cases, which impacts the generalizability of these particular findings.

Common questions about Mittoval (FAQ)

Q: What is Mittoval and what is it used for?

A: Mittoval is a prescription medication used to treat high blood pressure (hypertension) in adults. It belongs to a class of drugs called angiotensin II receptor blockers (ARBs). By blocking a substance in the body that causes blood vessels to narrow, Mittoval helps to relax the blood vessels, allowing blood to flow more easily and thereby lowering blood pressure. Treating high blood pressure helps prevent strokes, heart attacks, and kidney problems.

---

Q: How should I take Mittoval?

testimonios

A: You should take Mittoval exactly as your healthcare provider prescribes. Do not take more or less than the prescribed dose. It is typically taken once daily, with or without food. Try to take it at the same time each day to help you remember. If you miss a dose, take it as soon as you remember. If it is almost time for your next dose, skip the missed dose and return to your regular dosing schedule. Do not take two doses at once.

---

Q: What are the common side effects of Mittoval?

A: The most common side effects of Mittoval are usually mild and may include:

• Dizziness or lightheadedness, especially when standing up quickly.
• Headache.
• Fatigue or tiredness.
• Upper respiratory tract infection symptoms, such as a stuffy nose or sore throat.

Most of these side effects tend to lessen as your body adjusts to the medication. If any side effect persists or worsens, consult your healthcare provider.

---

Q: Who should not take Mittoval?

A: Mittoval is not suitable for everyone. You should not take Mittoval if you:

• Are pregnant or planning to become pregnant. Mittoval can harm an unborn baby.
• Are allergic to Mittoval or any of its ingredients.
• Have a condition called hereditary or idiopathic angioedema (severe swelling).
• Are taking certain other medications, particularly those containing aliskiren, and you have diabetes or kidney problems.

Always tell your doctor about all your medical conditions and all the medicines you take before starting Mittoval.

---

Q: Can I drink alcohol while taking Mittoval?

A: It is generally recommended to limit or avoid alcohol while taking Mittoval. Alcohol can further lower your blood pressure, which may increase the risk of side effects like dizziness, lightheadedness, or fainting. Discuss your alcohol consumption with your healthcare provider to understand what is safe for you.

---

Q: Does Mittoval interact with other medications?

A: Yes, Mittoval can interact with several other medications, which may affect how well Mittoval or the other medicines work, or increase the risk of side effects. Key interactions include:

• Diuretics (water pills) or other blood pressure medications: Can lead to excessive blood pressure lowering.
• Potassium supplements or potassium-sparing diuretics: Can increase the risk of high potassium levels (hyperkalemia).
• Nonsteroidal anti-inflammatory drugs (NSAIDs), such as ibuprofen or naproxen: May reduce the blood pressure-lowering effect of Mittoval and could worsen kidney function.
• Lithium: Mittoval can increase the level of lithium in your blood, which may lead to toxicity.

Always provide your healthcare provider with a complete list of all prescription, over-the-counter, and herbal products you are taking.

How to Store and Dispose of Mittoval

The storage and disposal of Mittoval (Alfuzosin Hydrochloride extended-release tablets) must follow official regulatory requirements to maintain product stability and safety.

Requirement	Official Instruction
Storage Temperature	Store at Controlled Room Temperature, 20 C to 25 C (68 F to 77 F).
Environmental Protection	Keep tablets in a tightly closed, light-resistant container, away from excess heat and moisture.
Handling Restriction	Do not crush, chew, or split the extended-release tablets.
Child Safety	Keep this medication strictly out of the reach of children.
Disposal	Dispose of any unused or expired product according to local regulatory requirements or utilize a drug take-back program.

These instructions ensure the integrity of the medication's controlled-release mechanism and adherence to safety mandates.